HOME >> BIOLOGY >> NEWS
Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting

is the only tumor necrosis factor (TNF) inhibitor approved for use without methotrexate. It is also the only TNF inhibitor approved for use as a first-line therapy for RA.

ENBREL acts by binding TNF, one of the dominant cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that cause the inflammatory process of RA and psoriatic arthritis. ENBREL competitively inhibits binding of TNF molecules to the TNF receptor sites. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.

SINCE THE PRODUCT WAS FIRST INTRODUCED, SERIOUS INFECTIONS, SOME INVOLVING DEATH, HAVE BEEN REPORTED IN PATIENTS USING ENBREL. MANY OF THESE INFECTIONS OCCURRED IN PATIENTS WHO WERE PRONE TO INFECTIONS, SUCH AS THOSE WITH ADVANCED OR POORLY CONTROLLED DIABETES. RARE CASES OF TUBERCULOSIS HAVE ALSO BEEN REPORTED. ENBREL SHOULD BE DISCONTINUED IN PATIENTS WITH SERIOUS INFECTIONS. DO NOT START ENBREL IF YOU HAVE AN INFECTION OF ANY TYPE OR IF YOU HAVE AN ALLERGY TO ENBREL OR ITS COMPONENTS. ENBREL SHOULD BE USED WITH CAUTION IN PATIENTS PRONE TO INFECTION. CONTACT YOUR PHYSICIAN IF YOU HAVE ANY QUESTIONS ABOUT ENBREL OR INFECTIONS.

There have been rare reports of serious nervous system disorders such as multiple sclerosis, seizures or inflammation of the nerves of the eyes. Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL. There have also been rare reports of serious blood disorders, some involving death. Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness. It is unclear if ENBREL (etanercept) has caused these nervous system or blood disorders. If your doctor confirms serious blood problems, you may need to stop using ENBREL.

The most frequent adverse events in placebo-controlled clinical trials involvin
'"/>


12-Nov-2001


Page: 1 2 3 4 5

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. OneWorld Health completes enrollment, treatment in Phase III India trial
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
6. KEPPRA international Phase IV SKATE study results show favourable efficacy
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Phase III, 48-Wk NEAT study results comparing GW433908 to Nelfinavir presented today
9. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
10. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
11. Phase transition in bilayers could affect their performance

Post Your Comments:
(Date:10/14/2014)... Scientists from The Scripps Research Institute (TSRI) have been ... (NIH) to lead an investigation of Lassa fever virus, ... The study aims to understand how Lassa fever virus ... survive the inflection. , "The ultimate goal is ... Lassa fever virus causes disease and develop new treatments ...
(Date:10/14/2014)... week, an international team of researchers, led by the ... the journal Nature Genetics a brief genomic ... varieties of the tomato plant. , The C.M. Rick ... important role in this study by providing seed of ... This study, which builds on the first tomato genome ...
(Date:10/14/2014)... October 14, 2014 – Over the past decades, we ... institutions to meet the needs of infants for social ... these infants to thrive. , Infancy and ... of the cortex. A generation of research suggests that ... cortical development and cognitive function. In contrast, deprivation and ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
(Date:10/19/2014)... 2014 The Asian Automatic patient billing ... analysis and forecast of revenue. The Automatic patient billing ... $463.9 million by 2018, at a developing CAGR of ... TOC of the Asian Automatic patient billing market, to ... also provides a glimpse of the segmentation of this ...
(Date:10/19/2014)... 2014 The Asian Orthopedic braces and support ... with analysis and forecast of revenue. The Orthopedic braces and ... around $416.5 million by 2018, at a developing CAGR of ... of the Asian Orthopedic braces and support systems market, to ... provides a glimpse of the segmentation of orthopedic braces and ...
(Date:10/18/2014)... 2014 The “Human Insulin Market- ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 2The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 3The Asian Orthopedic braces and support systems market is estimated to grow to around $416.5 million by 2018 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
Cached News: